These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

87 related items for PubMed ID: 8674002

  • 1. Serial serum c-erbB-2 levels in patients with breast carcinoma.
    Volas GH, Leitzel K, Teramoto Y, Grossberg H, Demers L, Lipton A.
    Cancer; 1996 Jul 15; 78(2):267-72. PubMed ID: 8674002
    [Abstract] [Full Text] [Related]

  • 2. Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy.
    Lipton A, Leitzel K, Ali SM, Demers L, Harvey HA, Chaudri-Ross HA, Evans D, Lang R, Hackl W, Hamer P, Carney W.
    Cancer; 2005 Jul 15; 104(2):257-63. PubMed ID: 15952182
    [Abstract] [Full Text] [Related]

  • 3. Elevated plasma tissue inhibitor of metalloproteinase-1 level predicts decreased response and survival in metastatic breast cancer.
    Lipton A, Ali SM, Leitzel K, Demers L, Evans DB, Hamer P, Brown-Shimer S, Pierce K, Carney W.
    Cancer; 2007 May 15; 109(10):1933-9. PubMed ID: 17407159
    [Abstract] [Full Text] [Related]

  • 4. Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662.
    Hayes DF, Yamauchi H, Broadwater G, Cirrincione CT, Rodrigue SP, Berry DA, Younger J, Panasci LL, Millard F, Duggan DB, Norton L, Henderson IC, Cancer and Leukemia Group B.
    Clin Cancer Res; 2001 Sep 15; 7(9):2703-11. PubMed ID: 11555582
    [Abstract] [Full Text] [Related]

  • 5. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer.
    Leitzel K, Teramoto Y, Konrad K, Chinchilli VM, Volas G, Grossberg H, Harvey H, Demers L, Lipton A.
    J Clin Oncol; 1995 May 15; 13(5):1129-35. PubMed ID: 7738618
    [Abstract] [Full Text] [Related]

  • 6. Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: results of two randomized double blind controlled multiinstitutional trials.
    Buzdar AU, Smith R, Vogel C, Bonomi P, Keller AM, Favis G, Mulagha M, Cooper J.
    Cancer; 1996 Jun 15; 77(12):2503-13. PubMed ID: 8640699
    [Abstract] [Full Text] [Related]

  • 7. Elevated serum levels of a c-erbB-2 oncogene product in oral squamous cell carcinoma patients.
    Chen CH, Lin YS, Lin CC, Yang YH, Ho YP, Tsai CC.
    J Oral Pathol Med; 2004 Nov 15; 33(10):589-94. PubMed ID: 15482324
    [Abstract] [Full Text] [Related]

  • 8. The course of serum HER-2/neu levels as an independent prognostic factor for survival in metastatic breast cancer.
    Schippinger W, Regitnig P, Bauernhofer T, Ploner F, Hofmann G, Krippl P, Wehrschütz M, Lax S, Carney W, Neumann R, Wernecke KD, Samonigg H.
    Oncol Rep; 2004 Jun 15; 11(6):1331-6. PubMed ID: 15138574
    [Abstract] [Full Text] [Related]

  • 9. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group.
    Buzdar AU, Jones SE, Vogel CL, Wolter J, Plourde P, Webster A.
    Cancer; 1997 Feb 15; 79(4):730-9. PubMed ID: 9024711
    [Abstract] [Full Text] [Related]

  • 10. Prognostic and predictive impact of the HER-2/ neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer.
    Müller V, Witzel I, Lück HJ, Köhler G, von Minckwitz G, Möbus V, Sattler D, Wilczak W, Löning T, Jänicke F, Pantel K, Thomssen C.
    Breast Cancer Res Treat; 2004 Jul 15; 86(1):9-18. PubMed ID: 15218357
    [Abstract] [Full Text] [Related]

  • 11. The presence of soluble c-erbB-2 in saliva and serum among women with breast carcinoma: a preliminary study.
    Streckfus C, Bigler L, Dellinger T, Dai X, Kingman A, Thigpen JT.
    Clin Cancer Res; 2000 Jun 15; 6(6):2363-70. PubMed ID: 10873088
    [Abstract] [Full Text] [Related]

  • 12. Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy.
    Sandri MT, Johansson HA, Zorzino L, Salvatici M, Passerini R, Maisonneuve P, Rocca A, Peruzzotti G, Colleoni M.
    Cancer; 2007 Aug 01; 110(3):509-17. PubMed ID: 17559147
    [Abstract] [Full Text] [Related]

  • 13. Serum epidermal growth factor receptor/HER-2 predicts poor survival in patients with metastatic breast cancer.
    Souder C, Leitzel K, Ali SM, Demers L, Evans DB, Chaudri-Ross HA, Hackl W, Hamer P, Carney W, Lipton A.
    Cancer; 2006 Nov 15; 107(10):2337-45. PubMed ID: 17048231
    [Abstract] [Full Text] [Related]

  • 14. Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen.
    Lipton A, Ali SM, Leitzel K, Demers L, Harvey HA, Chaudri-Ross HA, Brady C, Wyld P, Carney W.
    J Clin Oncol; 2003 May 15; 21(10):1967-72. PubMed ID: 12743150
    [Abstract] [Full Text] [Related]

  • 15. Serum levels of HER2 ECD can determine the response rate to low dose oral cyclophosphamide and methotrexate in patients with advanced stage breast carcinoma.
    Sandri MT, Johansson H, Colleoni M, Zorzino L, Passerini R, Orlando L, Viale G.
    Anticancer Res; 2004 May 15; 24(2C):1261-6. PubMed ID: 15154657
    [Abstract] [Full Text] [Related]

  • 16. High circulating HER2 extracellular domain levels correlate with reduced efficacy of an aromatase inhibitor in hormone receptor-positive metastatic breast cancer: a confirmatory prospective study.
    Colomer R, Llombart-Cussac A, Lloveras B, Ramos M, Mayordomo JI, Fernández R, Tusquets I, Gil M, Barnadas A, Constenla M, Gilabert M, Alba E.
    Cancer; 2007 Nov 15; 110(10):2178-85. PubMed ID: 17926331
    [Abstract] [Full Text] [Related]

  • 17. Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer.
    Lipton A, Ali SM, Leitzel K, Demers L, Chinchilli V, Engle L, Harvey HA, Brady C, Nalin CM, Dugan M, Carney W, Allard J.
    J Clin Oncol; 2002 Mar 15; 20(6):1467-72. PubMed ID: 11896093
    [Abstract] [Full Text] [Related]

  • 18. Fadrozole hydrochloride in postmenopausal patients with metastatic breast carcinoma.
    Miller AA, Lipton A, Henderson IC, Navari R, Mulagha MT, Cooper J.
    Cancer; 1996 Aug 15; 78(4):789-93. PubMed ID: 8756373
    [Abstract] [Full Text] [Related]

  • 19. Relationship of serum HER-2/neu and serum CA 15-3 in patients with metastatic breast cancer.
    Ali SM, Leitzel K, Chinchilli VM, Engle L, Demers L, Harvey HA, Carney W, Allard JW, Lipton A.
    Clin Chem; 2002 Aug 15; 48(8):1314-20. PubMed ID: 12142389
    [Abstract] [Full Text] [Related]

  • 20. Changes over time of extracellular domain of HER2 (ECD/HER2) serum levels have prognostic value in metastatic breast cancer.
    Bramwell VH, Doig GS, Tuck AB, Wilson SM, Tonkin KS, Tomiak A, Perera F, Vandenberg TA, Chambers AF.
    Breast Cancer Res Treat; 2009 Apr 15; 114(3):503-11. PubMed ID: 18437556
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.